Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A.
PRICE/OCF RATIO
N/A
Market Cap
$11.34B
Price/OCF Ratio
38.87
TTM Avg
34.89
3Y Avg
36.96
5Y Avg
40.86
Market Cap
$11.45B
Price/OCF Ratio
15.15
TTM Avg
17.52
3Y Avg
23.12
5Y Avg
26.57
Market Cap
$10.59B
Price/OCF Ratio
28.48
TTM Avg
25.82
3Y Avg
35.11
5Y Avg
24.38
Market Cap
$10.54B
Price/OCF Ratio
12.24
TTM Avg
14.86
3Y Avg
23.20
5Y Avg
25.79
Market Cap
$12.16B
Price/OCF Ratio
9.99
TTM Avg
9.77
3Y Avg
10.05
5Y Avg
9.05
Market Cap
$10.44B
Price/OCF Ratio
21.11
TTM Avg
15.95
3Y Avg
20.23
5Y Avg
27.13
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $11.33B | N/A | N/A | N/A | N/A |
| Bio-Techne Corporation (TECH)vs › | $11.34B | 38.87 | 34.89 | 36.96 | 40.86 |
| Align Technology, Inc. (ALGN)vs › | $11.45B | 15.15 | 17.52 | 23.12 | 26.57 |
| DaVita Inc. (DVA)vs › | $11.66B | 5.47 | 6.00 | 6.17 | 5.84 |
| Molina Healthcare, Inc. (MOH)vs › | $10.59B | 28.48 | 25.82 | 35.11 | 24.38 |
| Globus Medical, Inc. (GMED)vs › | $10.54B | 12.24 | 14.86 | 23.20 | 25.79 |
| Encompass Health Corporation (EHC)vs › | $12.16B | 9.99 | 9.77 | 10.05 | 9.05 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.44B | 21.11 | 15.95 | 20.23 | 27.13 |
| Insulet Corp. (PODD)vs › | $10.43B | 20.11 | 30.57 | 54.30 | 129.78 |
| Henry Schein, Inc. (HSIC)vs › | $10.35B | 14.77 | 15.55 | 14.45 | 15.08 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute